AJ Vaccines

Executive Summary

AJ Vaccines is a Danish private pharmaceutical company headquartered in Copenhagen, with a heritage spanning over a century in vaccine development and manufacturing. The company specializes in vaccines, diagnostics, and therapeutics for serious infectious diseases, with a strong emphasis on global public health initiatives such as polio eradication. Its product portfolio includes inactivated polio vaccine (IPV), oral polio vaccine (OPV), and other routine vaccines like DTaP and Td. AJ Vaccines operates as a commercial entity serving international organizations like UNICEF and WHO, leveraging its legacy facilities and expertise in vaccine production. The company's mission centers on improving global access to preventative healthcare, particularly in low- and middle-income countries. Despite being private and lacking a public ticker, AJ Vaccines holds a strategic position in the vaccine supply chain due to its dedicated manufacturing capacity and WHO prequalification for key products. The company faces headwinds from competitive pressure and the cyclical nature of vaccine procurement, but it benefits from long-term demand driven by global health priorities. Recent investments in next-generation production technologies and potential expansion into combination vaccines could drive growth. While specific financials are undisclosed, the company's role in pandemic preparedness and endemic disease control underpins its stability. Conviction in the company is moderate, given its niche focus and reliance on government and multilateral contracts, but the essential nature of its products provides a floor for valuation.

Upcoming Catalysts (preview)

• Q3 2026WHO prequalification of a new hexavalent combination vaccine (DTaP-IPV-Hib-HepB)65% success
• Q2 2026Award of a multi-year supply contract with Gavi for polio vaccines80% success
• Q4 2026Announcement of a strategic manufacturing partnership for pandemic preparedness55% success